Condition
Inflammaging
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Not Yet Recruiting2
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07395921Not ApplicableNot Yet Recruiting
Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.
NCT07372417Not Yet Recruiting
Macrophage/Monocyte Driven Inflammation and Anesthetic Sensitivity in Aging
NCT04983017Not ApplicableTerminated
2021 PMT iAge® Intervention Trial by Edifice Health
NCT03308747Not ApplicableCompletedPrimary
Inflammaging and Muscle Protein Metabolism
Showing all 4 trials